Aureomycin

Chlortetracycline

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	By mouth, IV, topical
ATC code	A01AB21 (WHO) D06AA02 (WHO) J01AA03 (WHO) S01AA02 (WHO) QG51AA08 (WHO) QJ51AA03 (WHO)
Pharmacokinetic data
Bioavailability	30%
Protein binding	50 to 55%
Metabolism	Hepatic (75%)
Biological half-life	5.6 to 9 hours
Excretion	Renal and biliary
Identifiers
IUPAC name (4S,4aS,5aS,6S,12aR)-7-Chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
CAS Number	57-62-5 Y
PubChem CID	54675777
ChemSpider	10469370 Y
UNII	WCK1KIQ23Q
KEGG	D07689 Y
ChEMBL	CHEMBL456066 N
E number	E702 (antibiotics)
ECHA InfoCard	100.000.310
Chemical and physical data
Formula	C22H23ClN2O8
Molar mass	478.882 g/mol
3D model (Jmol)	Interactive image
Melting point	168 to 169 °C (334 to 336 °F)
SMILES CN(C)[C@@H]2C(\O)=C(\C(N)=O)C(=O)[C@@]3(O)C(/O)=C4/C(=O)c1c(O)ccc(Cl)c1[C@@](C)(O)[C@H]4C[C@@H]23
InChI InChI=1S/C22H23ClN2O8/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21/h4-5,7-8,15,26,28-29,32-33H,6H2,1-3H3,(H2,24,31)/t7-,8-,15-,21-,22-/m0/s1 Y Key:CYDMQBQPVICBEU-XRNKAMNCSA-N Y
NY (what is this?)

Chlortetracycline (trade name Aureomycin, Lederle) is a tetracycline antibiotic, the first tetracycline to be identified. It was discovered in 1945 by Benjamin Minge Duggar working at Lederle Laboratories under the supervision of Yellapragada Subbarow. Duggar identified the antibiotic as the product of an actinomycete he cultured from a soil sample collected from Sanborn Field at the University of Missouri. The organism was named Streptomyces aureofaciens and the isolated drug, Aureomycin, because of their golden color.

In veterinary medicine, chlortetracycline is commonly used to treat conjunctivitis in cats.

Chlortetracycline may increase the anticoagulant activities of acenocoumarol. The risk or severity of adverse effects can be increased when chlortetracycline is combined with acitretin, adapalene, or alitretinoin. Aluminum phosphate and aluminum hydroxide can cause decreases in the absorption of chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. The therapeutic efficacy of mecillinam (amdinocillin), amoxicillin, and ampicillin can be decreased when used in combination with chlortetracycline. Chlortetracycline may increase the neuromuscular blocking activities of atracurium besilate.